Biopharmaceutical company developing therapies for metabolic and endocrine disorders.
Viking Therapeutics, Inc. is a dynamic clinical-stage biopharmaceutical company focused on advancing innovative treatments for metabolic and endocrine disorders. At the forefront of its development efforts is VK2809, the company's lead drug candidate. VK2809 is an orally administered, selective agonist of the thyroid hormone receptor beta (TRß), currently undergoing Phase IIb clinical trials. It aims to address biopsy-confirmed non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), two prevalent and challenging liver conditions.
In addition to VK2809, Viking Therapeutics is advancing VK5211, an orally available non-steroidal selective androgen receptor modulator (SARM). This compound is in Phase II clinical trials and targets patients recovering from non-elective hip fracture surgery, addressing muscle and bone health. The company's pipeline also includes VK0612, an orally administered drug candidate positioned for Phase IIb readiness in treating type 2 diabetes, and VK0214, an oral agonist of TRß designed for X-linked adrenoleukodystrophy, a rare genetic disorder.
Founded in 2012 and headquartered in San Diego, California, Viking Therapeutics combines scientific expertise with innovative research to develop transformative therapies. The company's strategic focus on modulating hormone receptors underscores its commitment to addressing unmet medical needs and improving patient outcomes across a spectrum of metabolic disorders.
With a dedicated team and a robust pipeline of promising candidates, Viking Therapeutics continues to drive advancements in biopharmaceutical research. Through collaborations and clinical partnerships, the company aims to accelerate the development and commercialization of novel therapies that offer new hope to patients worldwide.